Overview
This is a 2025 peer-reviewed mechanistic review by Wagner A. Tamagno and Jennifer L. Freeman of the School of Health Sciences, Purdue University (West Lafayette, IN), published in Toxics (MDPI) under a CC BY 4.0 open-access license. The paper synthesizes evidence from cell culture, invertebrate (Caenorhabditis elegans), zebrafish, rodent, non-human primate, and human studies on the molecular mechanisms by which lead (Pb) disrupts glutamatergic neurotransmission. The review covers ionotropic and metabotropic glutamate receptors, glutamate transporters, vesicular release machinery, metabolic cycling via the tricarboxylic acid (TCA) cycle and glutamate-glutamine shuttle, and the downstream consequences for glutathione synthesis and antioxidant defense. This paper contains no original measurements and reports no measured concentrations; it is mechanistic context for the lead neurotoxicity endpoint that underlies every modern lead reference value.
Study design
Narrative review. The authors searched published primary literature across in vitro, animal model, and human epidemiological sources; no systematic review protocol or PRISMA reporting is described. The review is organized around specific molecular targets — voltage-gated calcium channels (VGCCs), ionotropic receptors (NMDA and AMPA), metabotropic receptors (mGluRs), excitatory amino acid transporters (EAATs, primarily EAAT1/GLAST and EAAT2/GLT-1), sodium-coupled neutral amino acid transporters (SNATs), vesicular glutamate transporters (VGLUTs), SNARE complex proteins, TCA cycle enzymes, and glutathione synthesis pathways — and links each target’s disruption to behavioral or cognitive phenotypes. Table 1 (p. 6) is the primary synthesis table, mapping glutamatergic targets to primary molecular effects and corresponding behavioral phenotypes. Figure 1 (p. 5) illustrates normal glutamatergic signaling loops; Figure 2 (p. 16) illustrates the Pb-induced disruptions.
Sample size
Not applicable. This is a review; no samples were collected or analyzed.
Methods
No primary analytical methods, instruments, limits of detection, or limits of quantification are reported. No certified reference materials (CRMs) were used. All mechanistic claims are drawn from cited primary studies. The paper acknowledges that speciation and solubility of lead compounds (e.g., lead acetate forming insoluble complexes with phosphate or sulfate ions in cell culture media) critically affect the bioavailable fraction of Pb2+ in dose-response experiments and that this has implications for interpreting cell-based study results (p. 7).
Key findings
The overarching mechanistic frame is lead’s mimicry of divalent cations: Pb2+ competes with Ca2+ and Zn2+ at critical regulatory sites due to its similar ionic radius and charge, disrupting calcium homeostasis in both presynaptic and postsynaptic compartments.
Ionotropic glutamate receptors. Pb2+ acts as a non-competitive antagonist of NMDA receptors (NMDARs), preferentially inhibiting GluN2A-containing receptor subunits in a voltage-independent manner and downregulating GluN2A and GluN1 splice variant expression in the hippocampus. This blocks the calcium influx required for long-term potentiation (LTP) and impairs CaMKII and CREB phosphorylation. Developmental Pb2+ exposure has been associated with increased apoptosis during critical periods of brain formation in mammalian and zebrafish models. AMPA receptors are indirectly affected through Pb2+‘s interference with Zn2+, which modulates AMPA receptor surface trafficking and expression (Table 1, p. 6).
Metabotropic glutamate receptors. mGluR5 mRNA and protein expression are decreased by Pb2+ in a dose-dependent manner, impairing LTP and attenuating synaptic plasticity mechanisms for learning and memory. Pb2+ also disrupts Ca2+ in PKC activation and calmodulin interactions, disturbing downstream signaling cascades essential for mGluR function (pp. 8-9).
Glutamate transporters (EAATs). EAAT3 protein expression is increased in Pb-exposed rodent brains, interpreted as a compensatory response to elevated extracellular glutamate; however, this upregulation is insufficient to counteract excessive glutamate release. EAAT2 (GLT-1) appears particularly susceptible to downregulation by Pb, in part because GLT-1 expression depends on BDNF and TGF-alpha signaling, both disrupted by Pb-induced neurotoxicity. Pb-impaired mitochondrial function reduces ATP availability, compromising the Na+ gradient required for EAAT-mediated co-transport, thereby exacerbating extracellular glutamate accumulation (pp. 9-11). Inflammatory cytokines including IL-1beta and TNF-alpha, released following Pb-induced astrocyte and microglia activation, further modulate EAAT expression post-translationally (p. 11).
Vesicular release machinery. Pb2+ reduces the number of VGLUT1-positive synaptic elements that co-express synapsin, decoupling transporter presence from functional neurotransmitter release. Synaptotagmin levels are reduced in Pb-exposed neurons, slowing neurotransmitter exocytosis kinetics. Synaptobrevin, a critical vesicular SNARE protein, is reduced following developmental Pb2+ exposure, impairing SNARE complex assembly and vesicle fusion (pp. 11-13).
Glutamate metabolism. Pb2+ interferes with TCA cycle function by impairing isocitrate dehydrogenase and alpha-ketoglutarate dehydrogenase activity via calcium overload, reducing alpha-ketoglutarate availability for glutamate biosynthesis. Pb2+ may directly inhibit glutamate dehydrogenase (GDH) by altering its NAD+/NADH cofactor ratio through interaction with mitochondrial respiratory chain complexes II and III. Within the glutamate-glutamine shuttle, Pb2+ consistently reduces stimulated glutamate release in hippocampus and cortex (via disrupted Ca2+-dependent mechanisms) and impairs astrocytic glutamine synthetase (GS), compromising the glutamate recycling pathway (pp. 13-14).
Glutamate-GABA conversion. Pb2+ disrupts the glutamate-GABA cycle by reducing GAD expression, altering GABA-B receptor density and affinity in a dose- and time-dependent manner, and inhibiting VGCCs to diminish tetrodotoxin-sensitive GABA release. Regional differences are reported: increased [3H]-GABA binding in the cerebellum but decreased binding in the striatum after chronic Pb2+ exposure (p. 14).
Glutathione synthesis. Glutamate is a substrate for glutathione (GSH) synthesis via glutamate-cysteine ligase (GCL) and glutathione synthetase (GSS). Pb2+ exposure results in decreased GSH levels in neural tissue with concurrent increased lipid peroxidation and protein carbonylation. Pb2+ inhibits gamma-glutamylcysteine synthetase (the rate-limiting enzyme in GSH synthesis), and inhibits antioxidant enzymes including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), creating a vicious cycle in which Pb-induced glutamatergic disruption limits GSH synthesis and reduced antioxidant capacity in turn intensifies Pb toxicity (pp. 14-15).
Behavioral correlates. Table 1 (p. 6) provides the most systematic mapping from molecular target to behavioral phenotype. NMDAR inhibition is linked to memory impairments and increased anxiety-like behaviors. EAAT disruption leads to neurodegeneration, hyperexcitability, and anxiety- and seizure-like behaviors. Glutamine synthetase reduction produces chronic excitotoxic effects and neurocognitive decline. These phenotypes are observed in cell-based, zebrafish, rodent, and primate models; epidemiological data on childhood blood lead levels are referenced contextually (the 2017-2018 NHANES figure that 2.41% of Americans had blood lead levels at or below 3.5 microg/dL is cited at p. 2, and the US CDC Blood Lead Reference Value of 3.5 microg/dL at p. 3).
Evidence fitness
Context only (EF-4). This review contains no original exposure measurements, no concentration data for food or environmental matrices, and no dose-response data that could anchor a contamination profile. Its value is mechanistic: it provides the molecular-level explanation for the developmental neurotoxicity endpoint that underpins every modern lead reference value, and it maps specific receptor, transporter, and metabolic targets to behavioral phenotypes observed across model systems. It supports framing lead’s neurotoxicity hazard on the Lead page and complements quantitative dose-response sources such as EFSA 2010.
Limitations
Narrative review without a systematic search protocol; no PRISMA or equivalent reporting. The review does not formally assess study quality in cited primary literature. The majority of mechanistic evidence is from rodent and zebrafish models; extrapolation to human developmental exposures involves uncertainty. The concentration range of Pb2+ used in the cited in vitro studies may exceed environmentally relevant internal doses; the paper acknowledges this and notes that solubility issues in cell culture media affect dose-response interpretation. No primary human mechanistic data are reported.
Implications
Certification: This review establishes that the neurotoxicity endpoint driving lead standards operates specifically through glutamatergic disruption at multiple convergent molecular nodes. It reinforces that there is no safe level of developmental lead exposure (the NMDA antagonism and LTP impairment mechanisms lack a threshold). This supports the rationale for a stringent lead limit in infant and child food categories.
Courses: Primary reference for the lead neurotoxicology module. Table 1 is a teaching resource mapping receptor targets to behavioral phenotypes. The calcium mimicry mechanism and the NMDA-LTP-memory impairment chain are core concepts for QA and regulatory affairs audiences.
App: No contamination profile data; this source does not change any ingredient-level concentration estimate.
Microbiome: Not addressed in this paper.
Provenance notes
The local raw file is named Biochem_Lead_Amin_2025.pdf, which is misleading; the actual authors are Tamagno (W.A.) and Freeman (J.L.). “Amin” does not appear as an author in the published paper. The cite key uses the actual authorship. The paper is published open access under CC BY 4.0 (MDPI). Funding: National Institutes of Health, National Institute of Neurological Disorders and Stroke (R01NS130722), and the Institute for a Sustainable Future, Purdue University. PMID: 40710964; PMCID: PMC12300242.
Related evidence
Update history
No substantive edit history is available in this build. The full commit record is available in git.